MSD

What MSD does

MSD is the international trade name of Merck & Co., Inc., a US-headquartered global pharmaceutical company founded in 1891 and operating in the Netherlands since 1954. Its Dutch operations, anchored in Haarlem (production, packaging, and global distribution) plus Boxmeer and De Bilt (animal-health R&D and manufacturing), employ 5,000 people and supply medicines and vaccines to more than 140 countries, producing roughly 80 million vials and syringes of 10 vaccines annually from a mega-coldstore supported by 150,000 autonomous-vehicle trips per year.

The company's revenue model rests on three core streams: pharmaceutical product sales led by Keytruda (pembrolizumab, a PD-1 inhibitor that generated $31.7bn in global sales in 2025, ~49% of the $65bn group total); preventive vaccine sales, principally Gardasil for HPV and other vaccines distributed via government immunization programs (notably the India's nationwide HPV campaign targeting 1.15 crore girls through Gavi); and animal-health products (vaccines, the SenseHub cattle-monitoring platform, and Mectizan donation-stream products). Go-to-market is a hybrid of enterprise field sales to hospitals, oncologists and government health agencies, supplemented by DTC educational channels such as the DirectDocs TikTok/Instagram initiative and MSD Academy e-learning for healthcare professionals.

Strategically, MSD is realigning ahead of the 2028 Keytruda patent cliff through a February 2026 structural separation into an oncology division (Jannie Oosthuizen) and a non-oncology division (Brian Foard, ex-Sanofi), backed by ~$26bn in acquisitions (Verona Pharma, Cidara, Terns Pharma) and $2.2bn in AI-driven discovery alliances (Quotient, Mayo Clinic). MSD's AI/technology stack is genuinely differentiated at the drug-discovery layer (the company claims to have doubled its candidate pipeline and placed two AI-refined molecules in the clinic) and at the cold-chain logistics layer (outdoor AGVs, computer-controlled VNA cranes with 5mm accuracy, and CALM patient-side temperature sensors), though commercial AI products have not yet emerged.

Name

MSD

Legal name

Merck & Co., Inc.

Website

https://msd.nl

Company type

Public

Founded year

1891

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

MSD (Merck & Co., Inc.) is a global pharmaceutical company developing, manufacturing, and distributing medicines, vaccines, and animal-health products across oncology, infectious disease, chronic disease, and livestock, anchored by the Keytruda and Gardasil franchises and serving providers, governments, and patients in more than 140 countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAAAEAA

Prophylactic Human Vaccines (routine, pediatric, adult)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAAAEAK

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAJAHAB

Public & Private Vaccine Provider Networks (Clinics/Pharmacies/Physicians)

Healthcare & Life Sciences/Public Health, Government & Regulators/Immunization Programs & Vaccine Administration

SECONDARYBPADAIAB

Immunization & Vaccine Delivery Programs

Business & Public Services/International Organizations & Development/Global Health & Population Programs

SECONDARYHLAMAEAL

Veterinary Vaccines (Biologics)

Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

SECONDARYHLAMAKAM

Vaccine R&D, Clinical/Field Trials & Regulatory Affairs

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Vaccines

Keywords

• Pharmaceutical manufacturing
• Oncology immunotherapy
• Vaccine production
• Animal health products
• Drug discovery R&D

Headquarters

HQ city

Haarlem

HQ country

Netherlands

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: MSD generates revenue primarily through global sales of branded pharmaceutical products including Keytruda (pembrolizumab) at $31.7bn annual sales and other oncology, infectious disease, and chronic disease medications.
2. Vaccine Sales: MSD distributes approximately 190 million vaccine doses globally annually, including HPV vaccines (Gardasil) and other preventive vaccines.
3. Animal Health Products: MSD Animal Health division develops, manufactures and distributes veterinary vaccines and medications globally.
4. Licensing and Strategic Alliances: MSD generates revenue through strategic partnerships and licensing deals such as the $2.2bn alliance with Quotient and smaller co-development arrangements.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

MSD is a global biopharmaceutical company that develops, manufactures, and distributes prescription medicines, vaccines, and animal health products across oncology, infectious disease, chronic disease, and veterinary segments. Its flagship product is Keytruda (pembrolizumab), the world's top-selling cancer immunotherapy with $31.7 billion in global 2025 sales, supported by the Gardasil HPV vaccine franchise and a diversified pipeline. From its Dutch manufacturing base in Haarlem, MSD produces, packages, and distributes vaccines and medicines to more than 140 countries.

Product overview

MSD (known as Merck & Co outside the US and Canada) is a pharmaceutical company with a diversified portfolio spanning oncology, vaccines, infectious diseases, chronic diseases, and animal health. Core products include Keytruda (pembrolizumab), the world's top-selling cancer immunotherapy drug, and Gardasil, a leading HPV vaccine. The company operates through a platform-plus-acquisitions model, having completed major acquisitions including Verona Pharma ($10bn) and Cidara Therapeutics ($9.2bn) in 2025 to build its pipeline. MSD also offers specialized solutions like CALM for cold-chain medication adherence and SenseHub for livestock monitoring in its animal health division.

Differentiator

Problem solved

Functional benefit

Brands

• MSD Animal Health: Animal health division of MSD developing and manufacturing vaccines for animals
• MSD Academy

Products and services

• Keytruda (pembrolizumab) MSD's flagship PD-1 blocking antibody used as a cancer immunotherapy across multiple tumor types; the world's top-selling medication at $31.7bn in global sales in 2025, indicated for cancers including ovarian (combination therapy) and bladder.
• Gardasil / Gardasil-4 / Gardasil-9 HPV vaccines protecting against human papillomavirus strains 16, 18 and others to prevent cervical and other HPV-related cancers; supplied to India's national immunization program for 14-year-old girls through a Gavi partnership.
• Mectizan (ivermectin) Medication for the treatment and prevention of river blindness (onchocerciasis) and elephantiasis (lymphatic filariasis); MSD's Haarlem factory produces all tablets for the Mectizan Donation Program, with over 15 billion tablets produced to date.
• TERN-701 Oral BCR-ABL inhibitor in development for chronic myeloid leukemia, acquired through the Terns Pharma acquisition; positioned as a potential successor to Novartis' Scemblix.
• SenseHub Cattle monitoring system from MSD Animal Health that uses smart collars to monitor health, welfare, and fertility of cattle, with alerts for abnormal behavior related to rumination, feed intake, and heat detection.
• Verona Pharma respiratory portfolio Respiratory therapeutics acquired through MSD's $10 billion acquisition of Verona Pharma in 2025, intended to offset the revenue impact from the 2028 Keytruda patent cliff.
• Cidara Therapeutics portfolio Therapeutics acquired through MSD's $9.2 billion acquisition of Cidara Therapeutics in 2025 to strengthen MSD's pipeline ahead of Keytruda patent expiration.
• Quotient IBD alliance program Discovery program for new therapeutic targets in inflammatory bowel disease (ulcerative colitis and Crohn's disease) using Quotient's somatic genomics platform; MSD pays $20 million upfront plus milestones.
• Mayo Clinic AI drug discovery collaboration AI-augmented drug discovery collaboration between MSD and Mayo Clinic to accelerate development of new medicines.
• DirectDocs MSD Nederland initiative on TikTok and Instagram in which gynecologists provide short, medically accurate videos separating health facts from misinformation, with the first series focused on HPV and vaccination.

Quantifiable outcome

• 400,000+ patients treated with MSD oncology medicines in the past five years
• +4 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered major, minor and core.

• Terns PharmamajorOthers · 25 March 2026MSD acquired Terns Pharma for $6.7 billion all-cash ($53 per share, 31% premium). The acquisition provides MSD access to TERN-701 (oral BCR-ABL inhibitor for chronic myeloid leukemia) and additional metabolic and obesity drug candidates, strengthening the pipeline ahead of Keytruda's 2028 patent cliff.
• Quotient TherapeuticsmajorStrategic or Co-development Partner · 24 March 2026MSD entered a $2.2 billion alliance with Quotient Therapeutics to discover new therapeutic targets for inflammatory bowel disease. MSD pays $20 million upfront with additional development, regulatory, and commercial milestones. Quotient's somatic genomics platform identifies natural genetic variations linking genes to disease for conditions like ulcerative colitis and Crohn's disease. Quotient emerged from Flagship Pioneering and has previously partnered with Pfizer and GSK.
• WaivminorStrategic or Co-development Partner · 12 March 2026Waiv is a Paris-based AI precision oncology startup that partnered with MSD. Waiv's AI platform turns digital histopathology and multimodal clinical data into diagnostic tests for cancer care. Waiv maintains partnerships with global pharma companies including MSD.
• Verona PharmamajorOthers · 25 February 2026MSD acquired Verona Pharma for approximately $10 billion in 2025 as part of strategy to replenish portfolio ahead of Keytruda patent expiration.
• Cidara TherapeuticsmajorOthers · 25 February 2026MSD acquired Cidara Therapeutics for approximately $9.2 billion in 2025 to strengthen pipeline and offset revenue impact from patent expirations.
• Gavi (Vaccine Alliance)coreStrategic or Co-development Partner · 24 February 2026MSD supplies Gardasil-4 HPV vaccine to India's government vaccination program through Gavi partnership. India launched nationwide HPV vaccination campaign for 14-year-old girls targeting approximately 1.15 crore girls with single-dose WHO-approved vaccine.
• Mayo CliniccoreStrategic or Co-development Partner · 19 February 2026MSD and Mayo Clinic announced a collaboration on AI-driven drug discovery. The partnership aims to leverage AI capabilities to accelerate the development of new medicines.
• MYDAWA (Kenya)minorGTM or Marketing Partner · 10 December 2025Partnership between MSD and MYDAWA in Kenya as part of the Investing in Innovation Africa (i3) initiative to improve healthcare access across Africa, specifically related to cervical cancer prevention.
• i3 (Investing in Innovation Africa)minorStrategic or Co-development Partner · 10 December 2025i3 is a pan-African healthcare startup initiative funded by Bill & Melinda Gates Foundation. Three deals were announced including MSD and MYDAWA collaboration for healthcare access in Kenya.

Scale indicators20 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Pfizer: Global pharmaceutical company with leading oncology, vaccines, and primary care franchises. Directly comparable to MSD across immuno-oncology, HPV/pneumococcal vaccines, and post-LOE pipeline replacement strategies.
• Bristol Myers Squibb: Major immuno-oncology competitor (Opdivo) and key direct rival to Keytruda. Comparable to MSD in oncology pipeline depth, LOE exposure on blockbuster IO assets, and post-2028 replacement strategy.
• Roche: Global pharmaceutical leader in oncology, diagnostics, and vaccines. Comparable to MSD as a top-tier oncology competitor (Tecentriq, Polivy), with similar biologic/vaccine manufacturing scale and post-LOE pipeline reinvestment model.
• Novartis: Major oncology and specialty pharma peer. Direct comparator in hematology (Scemblix, relevant to MSD's TERN-701 acquisition), targeted oncology, and radioligand therapy adjacencies to MSD's immuno-oncology core.
• AstraZeneca: Global biopharmaceutical company with a strong oncology franchise (Imfinzi, Tagrisso, Enhertu). Comparable to MSD in immuno-oncology competition, ADC platform investments, and aggressive M&A-driven pipeline replenishment.
• Johnson & Johnson Innovative Medicine: Diversified pharma peer with oncology, immunology, and vaccines. Comparable to MSD in hematology/oncology, infectious disease vaccines, and post-LOE portfolio renewal through bolt-on M&A.
• GSK: Global vaccines and specialty medicines leader. Direct competitor in HPV (Cervarix successor), shingles (Shingrix), and adult vaccines, with comparable public-sector vaccine supply relationships and global cold-chain requirements.
• Sanofi: European-based global pharma with vaccines (Fluzone, Beyfortus), specialty care, and rare disease franchises. Comparable to MSD in vaccines manufacturing scale, immunology pipeline, and post-blockbuster portfolio diversification.
• Eli Lilly: Major pharma peer competing with MSD in oncology, diabetes, and chronic disease. Comparable in M&A appetite, R&D scale, and pipeline productivity, though more concentrated in metabolic/obesity categories.
• Zoetis: Global leader in animal health pharmaceuticals and vaccines. Direct peer to MSD Animal Health across livestock and companion animal vaccines, parasiticides, and livestock monitoring technology adjacencies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/msdnederland
• YouTubeyoutube.com/user/msdbvnl
• LinkedInlinkedin.com/company/msd-netherlands
• Instagraminstagram.com/msdnederland

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD